Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AveNEC: Avelumab in Advanced NEC G3
NCT03352934Phase 2Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Dec 2017
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in neuroendocrine carcinoma (NEC), Neuroendocrine Neoplasm (NEN), sponsored by Johannes Gutenberg University Mainz. Started Dec 2017; status: completed.
02
Drugs
avelumab
03
Conditions
neuroendocrine carcinoma (NEC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03352934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352934.